The G-protein coupled receptor (GPCR) gene family represents one of the largest families in the mammalian genome. The flexibility of signalling and widespread tissue distribution of these receptors has allowed GPCRs to be employed in the physiological regulation of nearly all biological functions. This, coupled with the fact that it is possible to chemically produce highly specific ligands to these receptors have made GPCRs attractive targets for pharmacological intervention in a wide variety of disease states. When targeting GPCRs in therapeutic drug design it is traditional, and eminently sensible, to focus on ligands that will provide agonism, antagonism or allosteric modulation. However, as more is understood of the mechanisms that regulate GPCRs, and in particular the dynamic covalent modifications that might endow tissue specific functions, then these regulatory processes may provide alternative targets for GPCR drug discovery. In this review we consider three of the covalent modifications which are considered to regulate the function of GPCRs namely; receptor phosphorylation, palmitoylation and ubiquitination. In particular, we will describe the mechanisms of modification, the functional consequences and the relationship between these three covalent modification events
INTRODUCTION
G-protein coupled receptors (GPCRs) are a diverse super-gene family representing ~1% of the mammalian genome. Although sharing very little sequence homology between subgroups of receptors, GPCRs all share the following features: they are all activated upon binding of an agonist, they exist as a single polypeptide chain that spans the plasma membrane seven times and they are able to initiate intracellular signalling via the activation of guanine nucleotide binding proteins (G-proteins) [1, 2] . Probably the most profound of these features is that a single agonist is able to activate just one or a small number of GPCRs. This exquisite selective activation process has been harnessed by nature to produce more than 670 different GPCRs that can be stimulated by a diverse array of agonists including hormones, growth factors, ions and light. In fact, the widespread deployment of these receptors as vehicles of cellular signal transduction has resulted in nearly all physiological processes being regulated, at least in part, by GPCRs (e.g. neurotransmission, secretion, cell growth and differentiation, apoptosis, smooth muscle contraction etc). The specificity of GPCR ligand-dependent activation and the widespread involvement of GPCRs in animal physiology have lent this protein family as perfect targets for pharmaceutical intervention for a wide variety of disease states. The success of targeting GPCRs in the treatment of human disease is evidenced by the fact that at least 70% of the pharmaceutical drugs on the market are directed against GPCRs.
Currently the strategy for drug targeting of GPCRs is to utilise the selective receptor:ligand binding properties to *Address correspondence to this author at the Department of Cell Physiology and Pharmacology, University of Leicester, Hodgkin Building, Lancaster Road, Leicester LE2 2RG. UK; Tel: 116 2522935; Fax: 116 2231405; E-mail: tba@le.ac.uk develop therapeutic agonists, antagonists, inverse agonists and allosteric modulators. This approach will undoubtedly continue to be the first port-of-call, particularly as our understanding of the structural requirements of ligand binding increases and the ligands selective for the large number of orphan receptors are discovered. However, an area that has been largely over-looked as a therapeutic target are the processes that regulate GPCR function. The reasons for this are obvious in that the enzymes involved in GPCR regulation are intracellular leading to issues of drug accessibility, that the regulatory mechanisms may not be specific to one receptor type therefore leading to a potential loss of selective targeting and that the processes that regulate GPCR function and coupling are largely still poorly understood. In this review we aim to address the last of these issues focusing on three regulatory processes for GPCRs, namely, receptor phosphorylation, palmitoylation and ubiquitination. In particular, we will discuss the relationship between these three covalent modifications and discuss the potential advantages of targeting these processes in drug discovery.
GPCR PHOSPHORYLATION
It is now clear that nearly all GPCRs are phosphorylated in response to agonist stimulation. This an area that has been extensively reviewed, (e.g. [3, 4] ) hence, only a brief description will be given here by way of background to the discussion of the role of receptor phosphorylation in palmitoylation and ubiquitination that will follow.
GPCRs are usually phosphorylated at multiple serine/theronine residues contained in the third intracellular loop and/or C-terminal tail although, more rarely, tyrosine phosphorylation has been reported [3, 4] . GPCR phosphorylation is a complex process involving both second messenger-regulated protein kinases such as PKC and PKA, and receptor specific kinases of the G-protein coupled receptor kinase (GRK) family [4] . There is also evidence that the casein kinase family can phosphorylate both mammalian and yeast GPCRs [5] . The large number of protein kinases capable of phosphorylating GPCRs correlates with the fact that GPCRs are phosphorylated at multiple sites and often in a hierarchal fashion [6] [7] [8] [9] . In a manner analogous to the receptor tyrosine kinase (RTK) family, the ability of GPCRs to be phosphorylated at a number of distinct sites leads to a potentially highly flexible adaptive mechanism that can be employed for specific regulatory purposes. However, for the majority of GPCRs how receptor phosphorylation is employed to regulate the coupling of receptors to signalling pathways is still uncertain.
The exception to this is the extensively studied β 2 -adrenergic receptor. Here phosphorylation by either PKA or the GRKs results in receptor uncoupling from the G s /adenylyl cyclase pathway [3, 4] . How PKA-mediated phosphorylation results in receptor:G-protein uncoupling, otherwise referred to as desensitisation, is unknown. However, in the case of GRK-mediated phosphorylation, receptor desensitisation is achieved by the recruitment of the adaptor protein, β-arrestin, to the phosphorylated receptor [3, 4, 10] . The binding of β-arrestin is through to sterically hinder the receptor:G-protein interaction.
The role of β-arrestin in GPCR signalling has recently been extended beyond simply desensitisation. The discovery that β-arrestin can bind to a large number of signalling proteins such as Src, ERK-1/2, AP2, and components of the JUN3-kinase pathway has suggested that this adaptor protein is able to couple the receptor to a variety of downstream signalling pathways [10] . It appears that this signalling role for β-arrestin can be utilised by a wide number of GPCRs and has led to the paradigm that nearly all GPCRs are phosphorylated in response to agonist-occupation and this results in the recruitment of β-arrestin that allows for receptor/Gprotein desensitisation and simultaneously links the receptor to signalling pathways such as intracellular tyrosine kinase activity [10] . However, the large number of GPCRs with diverse tissue distributions and physiological roles suggests that they are unlikely to be regulated in such a universal manner but rather that they will show considerable variation in their regulatory mechanisms and signalling properties. Nevertheless, there is accumulating evidence that β-arrestin plays a broad role in the regulation of GPCRs and that this adaptor protein is able to regulate GPCR signalling at a number of levels including, as will be discussed further, receptor ubiquitination.
GPCR PALMITOYLATION

Palmitoylation of GPCRs
The covalent attachment of lipid moieties to proteins was first described five decades ago [11] . Since then, this type of modification has been demonstrated on numerous viral and eukaryotic proteins making it one of the most common posttranslational modifications in eukaryotic cells. Four major types of lipid modification have been identified; (i) myristoylation, in which a C14 fatty-acid chain is attached through a stable amide linkage to an amino-terminal glycine residue; (ii) prenylation, in which either a farnesyl or a geranylgeranyl group is attached via a thioether linkage to a methylated C-terminal cysteine residue; (iii) glycosylphosphatidylinositol (GPI) anchor, attached to the protein though a carbohydrate moiety; and (iv) palmitoylation, in which a C16 fattyacid chain is attached either via a thioester linkage to cysteine residues (S-palmytoylation) or via an amide linkage to an N-terminal cysteine or glycine residue (N-palmitoylation).
The first report to demonstrate the palmitoylation of a GPCR was for bovine rhodopsin, published in 1984 [12] . The identification of the palmitoylation sites on the Cterminal tail of rhodopsin (Cys 322 and Cys 323 ), 14 amino acids down-stream of the seventh transmembrane domain [13] , led to the suggestion that this modification may result in the formation of a putative small fourth intracellular loop promoted by the integration of the palmitates into the lipid membrane bilayer. Later studies confirmed that this is indeed the case and suggested that the structural changes of the receptor C-terminal tail induced by the palmitate may then influence GPCR function [14, 15] . More recent analysis of bovine rhodopsin at the atomic level have indicated that the fourth intracellular loop is in fact an amphiphilic α-helix running parallel to the plasma membrane and is a structural consequence of palmitoylation that is likely to be present in nearly all GPCRs [16, 17] .
Soon after the identification in rhodopsin, covalent modification by palmitate of the β 2 -adrenergic receptor was confirmed [18] , followed by its homologue the α 2 -adrenergic receptor [19] . A large number of GPCRs now comprise an extensive list of receptors for which palmitoylation has been demonstrated, including luteinizing hormone/human choriogonadotropin [20, 21] , endothelin A [22] , serotonin 1B [23] , dopamine D 1 , D 2L and D 2s [24] [25] [26] , mGluR4 metabotropic glutamate [27] , thyrotropin [28] , vasopressin [29] , M 2 -muscarinic [30] and µ opioid receptors [31] among others ( Table 1) . It has been suggested that nearly 80% of GPCRs contain at least one potential cysteine palmitoylation site at a similar position to that of rhodopsin, 10 to 14 amino acids downstream of transmembrane domain seven [32] .
The involvement of palmitoylation in GPCR signalling is not restricted to the receptor. Palmitoylation is a widespread modification among numerous proteins involved in GPCR signalling, including the G-proteins [33] [34] [35] , effectors [36] [37] [38] , and regulatory proteins such as the GRKs [39, 40] .
Dynamic Nature of Protein Palmitoylation
It is now clear that proteins can go through cycles of palmitoylation and depalmitoylation. The reversibility of palmitoylation suggests that it has the potential to be a regulated modification much like protein phosphorylation. Given that palmitoylation provides a mechanism for binding cytosolic proteins to membranes [41] and for segregating proteins to microdomains [42, 43] , depalmitoylation and repalmitoylation could provide a mechanism to regulate membrane association and/or sorting.
The field is, however, split with regard to the existence of enzymes able to catalyse protein palmitoylation; so called protein acyl-transferases (PATs). Purification of PATs has proven very difficult. Despite this, a number of proteins containing protein acyl-transferase activity have been identified in yeast, Drosophila melogaster and mammalian cells. It is, however, also clear that the innate chemical reactivity of acyl-CoA can lead to spontaneous acyl transfer [44] . There are several examples of peptides and proteins that can undergo auto-acylation in vitro in the presence of palmitoylCoA [44] [45] [46] , including a peptide derived from the β 2 -adrenergic receptor [47] . The process of auto-acylation appears dependent to some degree on the amino acid sequence around the acylation site. Thus basic and hydrophobic residues promote auto-acylation, whereas acidic residues are inhibitory [47] . GPCRs can also undergo auto-acylation. Rhodopsin has been demonstrated to be spontaneously acylation in vitro [48] . However, the relevance that this event may have in vivo is not clear. In fact, it seems difficult to imagine how palmitoylation can provide a dynamic regulatory mechanism if the process of acyl-transfer to the target protein is not enzymatically controlled. Furthermore, in cells the binding of palmitoyl-CoA to proteins such as acylcoenzyme A binding protein will reduce the levels of free palmitoyl-CoA to a point that may not be able to support spontaneous palmitoylation. Nevertheless, it would appear likely that both enzymatic and non-enzymatic acyl-transfer is possible in cells. The relative contributions of these two processes is presently unknown.
If there is a palmitoylation/depalmitoylation cycle then there must be a mechanism for removing the palmitoyl group from proteins. Currently only two palmitoyl-thiolesterases (APTs) have been identified and characterized; Apt1 and Ppt1. Importantly, Apt1 is able to depalmitoylate G αi , G αs , RGS4, H-Ras and eNOS in vitro [49, 50] . It is worth noting that activated proteins are better substrates for Apt1. For example, Gα is a better substrate for Apt1 when it is not bound to Gβγ [49, 51] , and eNOS is a better substrate in vitro in the presence of Ca 2+ -calmodulin, which renders the active conformation of eNOS [50] .
The lack of a clear understanding of the enzymology of palmitoylation/ depalmitoylation has hindered our understanding of the impact of this covalent modification on the signalling process. It is, however, undisputed that many signalling proteins are able to undergo this cycle including a large number of GPCRs ( Table 1) .
Dynamic Nature of GPCR Palmitoylation
Despite the fact that nearly all GPCRs are palmitoylated at cysteines present in the C-terminal tail the dynamic nature of palmitoylation, particularly in response to agoniststimulation, depends on the receptor subtype. Hence, some receptors have increased palmitate incorporation on agonist stimulation whilst others show a decrease and others still show no effect of agonist occupation. In the case of the β 2 -adrenergic receptor, which is palmitoylated at cysteine 341 in the C-terminal tail [18] , agonist stimulation has been reported to mediated an increase in palmitate turnover [52] . Similar agonist-dependent changes in palmitoylation turnover have been reported for the α 2 -adrenergic [53] , M 2 -muscarinic [30] and 5-hydroxytryptamine (4a) [54] receptors. This increase in the rate of palmitate turnover at the receptor can indicate a change in the palmitoylation/ depalmitoylation cycle on agonist stimulation. It is not, however, possible to conclude that the overall palmitoylation status of the receptor is increased or decreased from these experiments. In contrast, the palmitate incorporation into the vasopressin V 2 receptor has been shown to be decreased on agonist stimulation [29] . Whereas other receptor subtypes, such as the A 1 adenosine [55] and 5-hydroxytryptamine (1A) [56] receptors, show no change in the palmitoylation status of the receptor following agonist stimulation. Hence, unlike the dogma associated with receptor phosphorylation where GPCRs are thought to be regulated in largely the same way by phosphorylation (see above), palmitoylation appears to be receptor specific and thereby can offer an adaptable regulatory mechanism that can be fine tuned for the particular needs of a specific receptor subtype.
Intriguingly, for some receptor subtypes the process of palmitoylation/depalmitoylation has been linked with receptor phosphorylation. The substitution of cysteine 341 with a glycine at the C-terminal tail of the β 2 -adrenergic receptor results in a receptor that is not palmitoylated in the basal state. This receptor mutant has also been shown to be hyperphosphorylated [57] . Substitution of the palmitoylated cysteines on the β 2 -adrenergic receptor appears to allow for agonist-independent phosphorylation of the receptor at the PKA and GRK sites, which in the wild type receptor are normally only phosphorylated following agonist occupation [58] . Not surprisingly, this mutant receptor showed high basal levels of phosphorylation with no increase in phosphorylation following agonist-stimulation. The receptor was also constitutively desensitised [57] . These studies suggested a model where the dynamic palmitoylation status of the β 2 -adrenergic receptor was directly linked with the phosphorylation of the receptor. It has been proposed that palmitoylation at the C-terminal tail provided a constraint on the β 2 -adrenergic receptor that prevented PKA phosphorylation at serines immediately downstream of the cysteine palmitoylation site [59] . On agonist stimulation the receptor became depalmitoylated allowing for PKA-mediated receptor phosphorylation [59] . This initiates a hierarchal phosphorylation process involving the subsequent phosphorylation of Cterminal serine and threonine residues by the GRKs [58] . This model places palmitoylation of the receptor at the centre of the adaptive regulatory processes of the β 2 -adrenergic receptor.
A similar scenario to that of the β 2 -adrenerigc receptor has been reported for a number of other receptors. Mutating two of the predicted palmitoylation sites in the C-terminal tail of the adenosine A 3 receptor resulted in a receptor that showed a hyper-phosphorylated basal state. This suggests that, similar to the β 2 -adrenergic receptor, GRK-mediated phosphorylation of the adenosine A 3 receptor possibly follows a sequential mechanism that involves firstly receptor depalmitoylation and then subsequent receptor phosphorylation. In addition, it has been reported that the palmitoylation of three cysteine residues in the C-terminal tail of the chemokine CCR5 receptor creates a fourth intracellular loop that is a necessary structural element important in transport of the receptor to the plasma membrane and functional aspects of the receptor including receptor sequestration, coupling to signalling pathways and receptor phosphorylation by the GRKs and PKC [60] [61] [62] .
Although these studies suggest a close relationship between receptor phosphorylation and palmitoylation, this is clearly not universally applicable. Studies on the vasopressin V 1A receptor have demonstrated that this receptor is palmitoylated at a double cysteine motif in the C-terminal tail [63] . Interestingly, agonist occupation of the V 1A -receptor resulted in an increase in the palmitoylation state of the receptor. Mutation of the two cysteine residues at the palmitoylation site in the C-terminal tail of the V 1A -receptor resulted in a dramatic reduction in palmitate incorporation into the receptor but did not eliminate entirely receptor palmitoylation. Significantly, the small remaining palmitoylation observed in the double cysteine mutant was still regulated by agonist suggesting that this receptor contained palmitoylation sites in addition to those at the C-terminal tail, and that these additional sites did show dynamic palmitoylation regulated following receptor occupation [63] . Of further importance was that the wild type V 1A -receptor showed a robust agonistmediated receptor phosphorylation [64] . However, the receptor mutant lacking the C-terminal tail palmitoylation sites resulted in a receptor that was only poorly phosphorylated by agonist occupation [63] . Similar to the β 2 -adrenergic receptor, these results suggest that the structural consequences of palmitoylation at the C-terminal tail has an important role in the phosphorylation of the V 1A receptor [63] . However, unlike the β 2 -adrenergic receptor where palmitoylation allows the receptor to adopt a conformation that prevents phosphorylation the opposite appears to be the case for the V 1A receptor where palmitoylation is required for efficient receptor phosphorylation.
There are also a number of GPCRs where the palmitoylation status does not affect the ability of the receptor to be phosphorylated. The M 2 -muscarinic receptor, for example, has a relatively short C-terminal tail which contains the cysteine palmitoylation site [30] . Mutation of the palmitoylation site in this receptor has no effect on receptor phosphorylation [30] which occurs at sites in the third intracellular loop [65] . Similarly, the bradykinin B 2 receptor, which incidentally has its phosphorylation sites at the C-terminal tail [6] and therefore might have been susceptible to the structural impact of palmitoylation within this domain, shows unaffected agonistmediated receptor phosphorylation in a palmitoylation deficient mutant [66] .
In conclusion, it is now clear that for some GPCRs palmitoylation can have a major impact on agonist-mediated phosphorylation probably by influencing the structure of the C-terminal domain and thereby the access of the receptor specific protein kinases. What is also clear is that the relationship between palmitoylation and phosphorylation is complex and receptor subtype specific. Thus, in some cases receptor phosphorylation is positively regulated by palmitoylation, in others negatively regulated and in others not affect at all by the palmitoylation status of the receptor. If this is linked with the fact that the extent of palmitoylation can be regulated by agonist occupation of the receptor, then it can be seen that palmitoylation can offer an extremely flexible modification with wide reaching consequences on receptor specific function.
Functional Consequences of Receptor Palmitoylation
It is probably of no surprise that the functional consequences of GPCR palmitoylation is dependent on the receptor subtype. In terms of G-protein coupling, for example, a large number of receptors appear to couple to G-proteins in a manner that is not affected by the palmitoylation status of the receptor [55, 63, 67] . In contrast, G-protein coupling of other receptors is dramatically influenced by receptor palmitoylation. This is particularly the case for the β 2 -adrenergic receptor where palmitoylation appears to play a central role in the phosphorylation and functional uncoupling of receptor from the G s -protein [58, 59] . In cases where palmitoylation is related to the ability of the receptor to be phosphorylated, as is the case for the β 2 -adrenergic receptor, it is not hard to rationalise how the palmitoylation state of the receptor might affect receptor:G-protein coupling. Furthermore, for the adenosine A 3 receptor [68] and luteinizing hormone receptor [69] where palmitoylation deficient mutants result in increased levels of receptor phosphorylation there is a consequential increase in the rate of internalisation of these receptors [70, 71] . This might be expected for GPCRs where internalisation is thought to be driven by the phosphorylation-dependent interaction of the receptor with β-arrestin [69, 71] .
However, this logical connection between palmitoylation, phosphorylation and receptor:G-protein coupling/ internalisation does not hold true for all GPCRs. For example, the rate of internalisation of a palmitoylation deficient mutant of the vasopressin V 1A receptor is dramatically increased compared with wild type receptor. This occurs despite the fact that the V 1A receptor mutant is less able to be phosphorylated in response to agonist occupation [63] . This is counterintuitive if one considers the widely accepted dogma that internalisation of GPCRs is mediated by phosphorylation.
A further unexpected finding from non-palmitoylated receptor mutants is that they revealed evidence for receptor:G-protein trafficking. The endothelin ET A is able to coupled to G o , G i and G q -proteins. A palmitoylation deficient mutant of this receptor coupled normally to G o -proteins but showed a reduced ability to couple to G q and G i -proteins [72] . Furthermore, removal of all three of the C-terminal tail cysteine palmitoylation sites in the endothelin ET B receptor rendered the receptor unable to couple to G q/11 and G iproteins [73] . Interestingly, if just one of these cysteines was removed then coupling to the G q/11 /phosphoinositide pathway was maintained but the ability to couple to G i -protein was lost [73] . These studies suggest that for some GPCR subtypes palmitoylation can regulate the ability of the receptor to couple to different G-proteins.
Another exciting possible functional consequence of the palmitoylation of GPCRs may be in membrane sorting, particularly in the localisation of receptors to cholesterol and sphingolipid-enriched domains or lipid rafts. For a number of proteins such as G-protein alpha subunits [33] and Src family tyrosine kinases [74, 75] palmitoylation has been associated with the targeting of proteins to lipid rafts. Recently, this function has been suggested for palmitoyl-moieties on GPCRs [42, 43] . Palmitoylation of the CCR5 receptor has been associated with targeting the receptor to lipid rafts [42, 60] thereby favouring its interaction with specific signalling proteins enriched in these particular membrane domains. Similarly, it has been suggested that translocation and clustering of N-formyl peptide [76] and gonadotropin-releasing hormone [77] receptors to rafts may be necessary to mediate receptor signalling activity.
In conclusion, it appears that palmitoylation of GPCRs has a wide range of potentially important functional consequences including, receptor trafficking, G-protein coupling, desensitisation and receptor internalisation ( Table 1) . Clearly, if agonist-stimulation can influence the palmitoylation status of the receptor, as has been described for a number of receptor subtypes (see above), then this covalent modification can potentially make a significance contribution to dynamic receptor regulation.
GPCR UBIQUITINATION The Ubiquitination of Proteins
The covalent attachment of ubiquitin, a 76 amino acid polypeptide, to target proteins plays a central role in a number of cellular responses including protein degradation, DNA-repair, cell cycle control and cell signalling (see [78] ). Attachment is achieved via a covalent isopeptide link between the C-terminal glycine on ubiquitin and the ε-amino group on lysine residues present on the target protein. Once attached, ubiquitin itself can act as a target for ubiquitin modification through one of three lysine residues (lysines 29, 48 and 63) resulting in poly-ubiquitination of the target protein [79] . The attachement of four or more ubiquitin moieties linking through lysine 48 is generally accepted as the signal for the protein to be targeted to the 26S proteasome for protein degradation [80] . Targeting proteins for proteasomal degradation is the most widely appreciated function of ubiquitination, however, there are a number of other important roles that this covalent modification plays. Poly-ubiquitination through lysine 63 on ubiquitin has been reported to have a number of non-proteolytic functions including regulation of the cell cycle [81] . Proteins can also be modified by a single ubiquitin in a process that appears in many cases to be reversible. This mono-ubiquitination has been implicated in the control of endocytosis and trafficking of endocytic proteins as well as DNA-repair, histone activity and virus budding [78, 79, 82] . The reversible nature of monoubiquitination has suggested that this form of ubiquitination can act in a regulatory capacity in a manner akin to protein phosphorylation.
Attachment of ubiquitin to a protein substrate requires the hierarchical action of three enzymes; ubiquitin-activating (E1), ubiquitin conjugating (E2) and ubiquitin-ligase (E3) (see Fig. 1 ). The first step in this process is the ATPdependent activation of the C-terminus of ubiquitin followed by its attachment to a cysteine residue (via a thiol-ester bond) in the active site of the E1 enzyme. The ubiquitin is then transferred to a cysteine in the active site of the E2 enzyme. Finally, ubiquitin is conjugated to a lysine residue on the target protein by the E3 ligase. There are two families of E3 ligase, called the RING-type and HECT-type. Ubiquitin Abbreviations: X = no data available; 5-HT = 5-hydroxytryptamine; LH/hCG = luteinizing hormone/human chorionic gonadotropin.
conjugation catalysed by the HECT-type E3 ligases involves the transfer of ubiquitin from E2 to a cysteine in the active site of the HECT-type ligase before transfer to the target protein. In contrast, RING-E3 ligases act more as adaptor proteins allowing for the transfer of ubiquitin from the E2 enzyme directly to the target protein. As well as facilitating the transfer of ubiquitin from E2 to the target protein, the RING-E3 ligases are thought to determine the specificity of the target proteins [79, 80] . Fig. (1) . Ubiquitination of substrate proteins. Ubiquitin (Ub) is activated in an ATP-dependent manner and is then attached to a cysteine in the active site of the E1 enzyme through a thiol-ester linkage. Ubiquitin is then transferred to the active site of E2 which then associates with the E3 ligase. The RING E3 ligases act as an adaptor protein allowing for the transfer of ubiquitin from the E2 to the substrate. In the case of HECT E3 ligases the ubiquitin is transferred to the HECT E3 ligase before being transferred to the substrate.
Yeast Receptor Ubiquitination
The first indication that GPCRs can be ubiquitinated came from studies of the yeast mating factor receptors. Saccharomyces cerevisiae have two pheromone receptor GPCRs, Ste2p and Ste3p, that respond to the peptides α-factor and the a-factor, respectively. These receptors show a high level of constitutive internalisation which can be increased by ~10 fold following agonist stimulation. Once internalised the yeast receptors do not recycle but rather are trafficked to the vacuole where they are degraded [83, 84] . This internalisation process has been found to be dependent on an interplay between receptor phosphorylation and ubiquitination.
Under basal conditions the yeast receptors are phosphorylated and reach a hyper-phosphorylated state in response to ligand [85] . The sites of phosphorylation on Ste2p are located at the C-terminal tail in the sequence SINNDAKSS [86] . Deletion of the serines within this sequence results in a phosphorylation deficient mutant that is unable to internalise [86] . Hence, at first glance, the internalisation of the yeast receptors appear to follow a similar phosphorylation-dependent mechanism as mammalian receptors. However, analysis of the fully sequenced yeast genome reveals that the process of phosphorylation and internalisation of yeast receptors occurs in the absence of homologs of both the GRKs and arrestins. Detailed examination of the protein kinases involved in Ste2p phosphorylation revealed that yeast casein kinase 1 (CK1) proteins, Yck1p and Yck2p, are responsible for the phosphorylation of the Cterminal serines [87] . Similarly, phosphorylation of the afactor receptor, Ste3p, at serines within a C-terminal tail PEST-like motif is mediated by Yck1p/2p [88] .
Although internalisation of Ste2p/3p is dependent on phosphorylation this is not the direct signal for yeast receptor internalisation. In addition to phosphorylation the receptors undergo agonist-dependent mono-ubiquitination at sites close to the C-terminal phosphorylation domain [86] . Using a Ste2p receptor fused to ubiquitin it was found that this receptor-fusion protein was able to internalise even if all of the phosphorylation sites were removed [87] . Thus, the ubiquitination of the C-terminal tail is sufficient to mediate internalisation of Ste2p. That phosphorylation is the signal for ubiquitination of Ste2p is evidenced by the fact that removal of the C-terminal phosphorylation sites prevented agonistmediated ubiquitination [86] . These studies concluded that yeast GPCRs are phosphorylated by CK1 in response to agonist at multiple serines in the C-terminal tail. This initiates mono-ubiquitination of lysine residues in the vicinity of the phosphorylation sites and subsequent internalisation and trafficking of the receptors to the vacuole, where they are degraded [85] [86] [87] [88] [89] .
Thus, yeast GPCRs display an intimate relationship between phosphorylation and ubiquitination. Although differing in mechanistic details, this relationship has also been described for a number of other proteins including, more recently, mammalian GPCRs.
Ubiquitination of Mammalian GPCRs
The ubiquitination of mammalian GPCRs was first identified in the chemokine CXCR4 receptor [90, 91] and has now been extended to a variety of other GPCRs including the β 2 -adrenergic receptor [92] , vasopressin V 2 receptor [93] , the platelet activating receptor [94] , the thyrotropin releasing hormone receptor [95] and the somatostatin sst 3 receptor [96] . However, unlike the situation in yeast, ubiquitination of mammalian receptors does not appear to be involved in receptor internalisation. Rather mammalian GPCR ubiquitination appears to play an important role in intracellular trafficking of the receptor through the endosome to the lysosome (a structure akin to the yeast vacuole) where the receptors are degraded.
The initial study on the CXCR4 receptor provided the essential elements that appears to be true for most of the GPCRs studied to date. The CXCR4 receptor appears to be internalised in an agonist-dependent manner via clathrin coated pits and sorted either to a pool of receptors that are rapidly recycled or to lysosomes where the receptor is degraded. Marchese and Benovic identified a sequence (SSLKILSKGK) in the C-terminal tail of the CXCR4 receptor that was essential for degradation of the receptor [90] . Removal of the serine residues prevented both receptor internalisation and lysosomal degradation whereas removal of the three lysines had no effect on receptor internalisation but prevented lysosomal degradation. Removal of the three lysines not only prevented receptor degradation but also attenuated agonist-dependent ubiquitination [90] . This suggested that a system somewhat similar to that seen in the yeast receptors may be in operation for the CXCR4 receptor. Namely, that phosphorylation of serines in the C-terminal tail of the CXCR4 receptor is the signal for clathrin mediated endocytosis, but also is able to initiate mono-ubiquitination of lysines in the vicinity of the phosphorylation sites. Monoubiquitination does not appear to contribute to receptor internalisation but rather trafficks the internalised receptor to the lysosome where the receptor was degraded. This sequence of events, although supported by the data [90] , is still not yet totally proven for the CXCR 4 receptor. For example, if this model were true then it would be expected that a phosphorylation deficient mutant of the receptor (i.e. the mutant lacking the three serines in the degradation motif) would not undergo agonist-dependent ubiquitination.
Work by Shenoy from the Lefkowitz group has developed the GPCR ubiquitination story further. They demonstrated that the β 2 -adrenergic receptor, is transiently ubiquitinated following agonist stimulation [92] . As in the case of the CXCR4 receptor, ubiquitination of the β 2 -adrenergic receptor does not appear to be involved in receptor internalisation but rather was important for receptor degradation [92] . The surprise was that receptor ubiquitination required the recruitment of β-arrestin. Whether β-arrestin is able to bind the E3 ligase responsible for β 2 -adrenergic receptor ubiquitination is not clear but would appear extremely likely. Particularly since both yeast two hydrid and co-immunoprecipitation studies determined that β-arrestin could form a complex with the E3 ligase, Mdm2 [92] . However, using Mdm2 null cells it was clear that Mdm2 was not the β 2 -adrenergic receptor E3 ligase [92] . Hence, the nature of the receptor E3 ligase and the possibility that β-arrestin acts as an adaptor protein for its recruitment to the receptor still remains to be established.
In addition, to the agonist-dependent ubiquitination of the β 2 -adrenergic receptor it was found that β-arrestin was also ubiquitinated in a transient manner. In this case β-arrestin ubiquitination was found to be dependent on receptor activation and was mediated by Mdm2, which was found in a complex with β-arrestin. Experimental procedures that inhibited β-arrestin ubiquitination were found to disrupt receptor internalisation [92] . Hence, the sequence of events that appears to be in operation for the β 2 -adrenergic receptor is that agonist-stimulation results in phosphorylation of the C-terminal tail of the receptor and the recruitment of β-arrestin. The receptor:β-arrestin complex is ubiquitinated both at the receptor and β-arrestin. The ubiquitination of β-arrestin is necessary for receptor internalisation and the ubiquitination of the receptor is necessary for trafficking the receptor to the lysosome and subsequent degradation [92, 97] .
It is interesting to focus on the role that receptor phosphorylation plays in this sequence of events. Unlike the situation found for the yeast GPCRs, phosphorylation of the β 2 -adrenergic receptor does not directly signal to the ubiquitin pathway but rather allows for the recruitment of an adaptor protein (β-arrestin) that is then able to couple the phosphorylated receptor to the ubiquitin-processing pathway. In this respect, phosphorylation plays a role similar to other well characterised phosphorylation-dependent ubiquitination pathways in mammalian cells. In particular, that of IκB which is targeted for degradation following phosphorylation by IκB kinase. Phosphorylated IκB binds to the WD40 repeat domain on β-TrCP which is the "receptor" or docking subunit of the RING E3 ligase complex SCF β-TrCP . Once complexed to the E3 ligase, phospho-IκB is then ubiquitinated and subsequently degraded [98] . A similar system may be in operation for the β 2 -adrenergic receptor, where receptor phosphorylation allows for the association with β-arrestin that acts in an analogous manner to β-TrCP by docking with an E3 ligase so forming a receptor:arrestin:E3 ligase complex that is able to drive ubiquitination of the β 2 -adrenergic receptor.
Role of Ubiquitin Binding Proteins in Plasma Membrane Protein Trafficking
Understanding the role of ubiquitin moieties in the intracellular trafficking of plasma membrane receptors has been hugely advanced by the identification of ubiquitin interacting proteins [82] . These proteins contain four types of specific ubiquitin binding domains; ubiquitin interacting motifs (UIM), ubiquitin associated domains (UBA), ubiquitin conjugating enzyme-like domains (UBC)/ubiquitin E2 variant domains (UEV) and Cue1-homolgous domains (CUE) [82] . These act as ubiquitin receptors able to complex with the cargo protein. The ubiquitin interacting proteins can themselves undergo ubiquitination resulting in the further recruitment of ubiquitin binding proteins so that a large complex results that is able to drive intracellular trafficking [99] .
In terms of cell surface receptors the role of ubiquitination in the trafficking of the epidermal growth factor receptor (EGF-R) is probably the best understood [100] . Termination of signalling of the EGF-R is achieved largely by clathrinmediated internalisation [101] followed by receptor degradation. This is an ubiquitin-dependent process initiated by ligand-induced tyrosine phosphorylation of the receptor which then results in the recruitment the EGF-R ubiquitin ligase, Cbl (Casitas B-lineage lymphoma), which in turn catalyses the mono-ubiquitination of multiple sites on the EGF-R [100] . The ubiquitinated EGF-R then interacts with UIM containing proteins Eps15 (EGF-R pathway substrate 15) and epsins which, in addition to interacting with distinct mono-ubiquitinated sites on the EGF-R, are able to interact with each other and with AP2 and clathrin [102] . This large multi-protein complex is formed at the plasma membrane but does not appear to be important for the internalisation of the EGF-R [103] . Rather the complex is important for the delivery of the receptor to the early "sorting" endosomes. It is the delivery of the internalised EGF-R complex to the sorting endosomes and the retention of the complex, via binding to other ubiquitin interacting proteins, that decides the fate of the internalised EGF-R. The default pathway is for the receptor to be recycled to the plasma membrane, thus EGF-R mutants unable to undergo ubiquitination are internalised and then recycled to the plasma membrane. However, the fate of wild type receptors is to be retained in the sorting endosomes by interacting with UIM containing proteins such has STAM and Hrs (hepatocyte growth factor receptor-regulated tyrosine kinase substrate) present on the early endosome [99] . Once retained in the endosomes, processing of the EGF-R is then initiated by delivery of the EGF-R complex to ESCRT I via the interaction with Tsg101/Vps 23 (tumour susceptibility gene product 101). From this point the receptor is processed through ESCRT complexes II and III before being deubiquitinated and then released via vesicle scission through the action of the AAA ATPase Vsp4 to the lysosome [99] .
In this model the ubiquitin-conjugation system is the key factor that controls the route taken by a receptor, namely recycling or processing through the endosomal ESCRT system through to lysosomal degradation. This decision making process has been described as a "shunt" where the preferred or default pathway is recycling but ubiquitination of the cargo (receptor) and the interaction of the ubiquitinated cargo with ubiquitin interacting proteins "shunts" the cargo protein to the endosome and subsequently to lysosomal degradation.
In addition to the EGF-R, the transferrin receptor can be targeted to the lysosome via an ubiquitin-dependent shunt. Under normal conditions the transferrin receptor is internalised through clathrin coated pits and recycled rapidly to the plasma membrane in an ubiquitin-independent fashion. However, a fusion protein containing transferrin-receptor fused to ubiquitin is able to association with the UIM containing endosomal ubiquitin receptor, Hrs. This association shunts the receptor from the recycling pathway to the ubiquitin-processing degradation pathway [103] .
GPCR Ubiquitination as a Shunt Mechanism in Trafficking Receptors to the Lysosome
There is some evidence that ubiquitin interacting proteins are involved in the endosomal sorting of GPCRs. Endosomal processing of the ubiquitinated CXCR4 receptor is dependent on the early endosomal ubiquitin receptor Hrs as well as the AAA ATPase, Vps4, which is involved in the final stages of ESCRT-mediated trafficking to the lysosome [104] . Furthermore, degradation of the δ-opioid receptor is dependent on Vps4 and Hrs [105] . However, ubiquitination of the δ-opioid receptor is not necessary for the lysosomal sorting of the receptor [106] . Hence, despite the fact that the δ-opioid receptor is not ubiquitinated the process of endosomal sorting of the receptor is dependent on elements of the ubiquitinsorting pathway. A similar situation has been reported for the growth hormone receptor, which is sorted to the lysosomes by a mechanism that is dependent on the ubiquitin-conjugation system but does not rely on ubiquitination of the receptor itself [107, 108] . In the case of the δ-opioid receptor the interaction of the C-terminal tail of the receptor with a protein called GASP is essential for processing of the internalised δ-opioid receptor [109] and appears to play an important role in coupling the receptor to elements of the ubiquitinsorting pathway.
As described above, the β 2 -adrenergic receptor is ubiquitinated in a manner that appears dependent on receptor phosphorylation and β-arrestin binding. Despite this process the β 2 -adrenergic receptor is actually relatively poorly retained at the early endosomes with only a small proportion being shunted to the lysosomal pathway. This is in stark contrast the vasopressin V 2 receptor which is internalised rapidly on agonist stimulation and almost exclusively trafficked through the endosomal pathway through to the lysosome [93] . The contrasting features of the β 2 -adrenergic receptor and the vasopressin V 2 receptor have been described in two classes of GPCR called; Class A and Class B receptors. The β 2 -adrenergic receptor is an example of a Class A receptor and is characterised by the fact that on agonist stimulation the receptor interacts preferentially with β-arrestin2. In Class A receptors the receptor:β-arrestin complex is not, however, sufficiently stable for the two proteins to be internalised together. The result is that Class A receptors are internalised without being complex to β-arrestin and subsequently are rapidly recycled to the plasma membrane [110, 111] . This is in contrast with the Class B receptors (e.g. vasopressin V 2 receptor) which interact equally well with both β-arrestin1 and 2 forming a stable complex that is internalised with the receptor. This receptor:β-arrestin complex is mainly retained in the endosomes where the receptor is trafficked eventually to lysosomes [110, 111] .
The key process in defining whether a receptor is a Class A or B receptor appears to lie in the stability of the receptor:β-arrestin complex. This in turn relies on the sustained ubiquitination state of the β-arrestin. Stimulation of the β 2 -adrenergic receptor results in transient ubiquitination of β-arrestin, whereas the vasopressin V 2 receptor mediates a sustained β-arrestin ubiquitination [93] . Swapping the Cterminal tail of the β 2 -adrenergic receptor with the C-tail of the V 2 receptor results in a chimeric β 2 -adrenergic receptor that is able to maintain ubiquitination of β-arrestin. This receptor now shows all of the characteristics of a Class B receptor and led to the suggestion that the ubiquitination state of the β-arrestin was the key determinant in intracellular trafficking of Class A and B GPCRs [93] . It was concluded that the stability of the receptor:β-arrestin complex is determined by the longevity of the ubiquitination of β-arrestin. The "ubiquitin" stablised receptor:β-arrestin complex is internalised with the receptor and is able to shunt the receptor to the degradative pathway. If, on-the-other-hand, the receptor induces transient ubiquitination of β-arrestin the receptor:β-arrestin complex is unstable allowing the receptor to be internalised without β-arrestin. Under these conditions the re-ceptor is not retained at the endosomes but rather is recycled to the plasma membrane [93] .
It has yet to be determined if Class B receptor:β-arrestin complexes utilise the ubiquitin interacting proteins at the endosomes to traffic through the endosome/ESCRT pathway. However, the GPCR:β-arrestin complex of Class B receptors are highly ubiquitinated and as such are broadly similar to the internalised EFG-R-complex that is able to dock with endosomal ubiquitin receptors and thereby be retained at the endosomes for subsequent degradation. Further study in this area is likely to reveal the full extent of the role that ubiquitin binding proteins play in the processing of internalised GPCRs.
CONCLUSION: THE COMPLEXITY OF G-PROTEIN COUPLED RECEPTOR SIGNALLING
One of the outstanding features of GPCRs is that a single receptor type activated by one physiological ligand can couple to multiple intracellular pathways. For example, the M 3 -muscarinic receptor, which is a "classical" G q/11 -coupled GPCR, when stimulated by acetylcholine can activate the G q/11 /phosphoinositide pathway resulting in the production of inositol 1, 4, 5 trisphosphate and diacylglycerol with a consequent increase in intracellular calcium and activation of PKC [112] . This event underlies the well established physiological processes regulated by this receptor, namely, smooth muscle contraction of the ileum, bladder and airways and exocrine secretion (i.e. salivary gland) [113] [114] [115] . However, detailed analysis of the signalling properties of the M 3 -muscarinic receptor demonstrate that it is able to activate at least nine other signalling pathways including the mitogen activated protein kinase pathways (JUN-kinase, ERK-1/1 and p38), the PLD pathway, PLA 2 , PI-3 kinase/akt pathway and processes leading to the protection of cells from apoptosis [112, [116] [117] [118] [119] . Although a number of these pathways are thought to be downstream of heterotrimeric G-protein activation, many of these pathways appear to be either in part or totally independent of G-protein coupling. This ability to couple to a large number of intracellular signalling pathways is a feature common to nearly all GPCRs and begs the obvious question; what is the physiological significance of this signalling promiscuity? Nature seems to have developed a system of fantastic selectivity on the extracellular surface, with just a single ligand able to activate a tiny fraction of the GPCR super-family, just to loss this selectivity on the intracellular face where the activated receptor is able to initiate an "explosion" of signalling.
The answer to this question may lie in studying GPCRs in their natural cellular environment. GPCR signalling has largely been studied in transfected cell models where receptors show a large degree of promiscuity. However, investigation in physiologically relevant cell types reveals that the extent of receptor promiscuity is often less extensive. For example, the M 3 -muscarinic receptor gives a robust ERK-1/2 response (between 10-20 fold over basal) in most immortalised cell models [119] . However, in cerebral cortical neurones the M 3 -muscarinic receptor does not couple to ERK-1/2 pathway despite the fact that the receptor is efficiently coupled to the G q/11 /phosphoinositide pathway [120] . Consistent with this are studies from our own laboratory that show that the M 3 -muscarinic receptor expressed in cerebellar granule cells can signal to the G q/11 /phosphoinositide pathway [121] but only poorly to ERK-1/2 (unpublished observation).
These studies may give a hint as to the reason for such a large degree of GPCR signalling promiscuity. A given GPCR subtype is often found in a number of diverse cell types; M 3 -muscarinic receptors are expressed, for example, in neurons of the cerebral cortex and cerebellum as well as exocrine cells in the salivary gland and smooth cells of the bladder [112] . In order for the receptor to perform the specific signalling role required in these different cell types the receptor must have a sufficiently flexible signalling repertoire so that the appropriate signalling for that particular cell type is employed. The factors that regulate the repertoire of signalling pathways accessible to a particular receptor in different tissues have yet to be determined. However, the possibility that covalent modification of GPCRs contribute to the coupling of GPCRs to specific signalling pathways is tantalising. Extensive studies on the β 2 -adrenergic receptor have suggested that receptor phosphorylation can traffic the receptor to specific G-proteins and that recruitment of the adaptor protein β-arrestin to the phosphorylated form of the receptor has been shown to not only to desensitise the receptor but also couple the receptor to components of the MAP kinase pathway and to cytosolic tyrosine kinases (see above).
Receptor phosphorylation is not the only covalent modification available to GPCRs. As discussed in this review it is now clear that nearly all GPCRs are palmitoylated at conserved cysteine residues in the C-terminal tail and in some cases this is a dynamic process controlled by agonist occupation of the receptor. Furthermore, GPCRs are also ubiquitinated in response to agonist as are components of the Gprotein signalling machinery such as β-arrestins. It is tempting to speculate that the ability of GPCRs to access signalling pathways may, in part, be regulated by these posttranslational modifications. It is also clear that these posttranslational modifications do not operate in isolation but have a complex relationship where each modification can influence the ability of the receptor to undergo further modifications. This complex interplay allows for further flexibility in the regulatory mechanism that ultimately results in the signalling output from a receptor and may offer a coordinated process of regulation that could underlie the tissue specific function of GPCRs. 
